

# Comparative safety of high-efficacy disease-modifying multiple sclerosis: a systematic review and network meta-analysis

Neurological Sciences

43, 5479-5500

DOI: [10.1007/s10072-022-06197-3](https://doi.org/10.1007/s10072-022-06197-3)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis. Journal of the American Pharmacists Association: JAPhA, 2023, 63, 8-22.e23.	0.7	12
3	Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2023, 71, 104581.	0.9	4
4	Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment. Journal of Neurology, 0, , .	1.8	0
5	Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis. Neurology and Therapy, 0, , .	1.4	2